Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis

Combining post-transplantation cyclophosphamide (PT-Cy), tacrolimus, and post-engraftment low-dose anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation from haplo-identical donors resulted in low cumulative incidences of 100-day grade II-IV acute GVHD (14.9±4.4%) and no cases of grade III-IV acute GVHD, according to data from a single center analysis including 67 patients.